MX2022001660A - Composiciones peg de péptidos catiónicos lipidados para la administración de ácidos nucleicos. - Google Patents

Composiciones peg de péptidos catiónicos lipidados para la administración de ácidos nucleicos.

Info

Publication number
MX2022001660A
MX2022001660A MX2022001660A MX2022001660A MX2022001660A MX 2022001660 A MX2022001660 A MX 2022001660A MX 2022001660 A MX2022001660 A MX 2022001660A MX 2022001660 A MX2022001660 A MX 2022001660A MX 2022001660 A MX2022001660 A MX 2022001660A
Authority
MX
Mexico
Prior art keywords
compounds
nucleic acid
cationic peptide
acid delivery
compositions
Prior art date
Application number
MX2022001660A
Other languages
English (en)
Inventor
Colin James Mckinlay
Original Assignee
Nutcracker Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutcracker Therapeutics Inc filed Critical Nutcracker Therapeutics Inc
Publication of MX2022001660A publication Critical patent/MX2022001660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se refiere a complejos y composiciones de compuestos catiónicos combinados con porcentajes en masa bajos de compuestos PEGilados, tales como lípidos PEGilados, para la administración de ácidos nucleicos y otras cargas polianiónicas a las células, métodos para preparar complejos y composiciones que comprenden uno o más compuestos catiónicos y un bajo porcentaje en masa de compuestos PEGilados con compuestos polianiónicos, y métodos para administrar los compuestos polianiónicos a las células.
MX2022001660A 2019-08-09 2020-08-07 Composiciones peg de péptidos catiónicos lipidados para la administración de ácidos nucleicos. MX2022001660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885022P 2019-08-09 2019-08-09
US201962907470P 2019-09-27 2019-09-27
PCT/US2020/045508 WO2021030218A1 (en) 2019-08-09 2020-08-07 Lipidated cationic peptide-peg compositions for nucleic acid delivery

Publications (1)

Publication Number Publication Date
MX2022001660A true MX2022001660A (es) 2022-04-18

Family

ID=72193637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001660A MX2022001660A (es) 2019-08-09 2020-08-07 Composiciones peg de péptidos catiónicos lipidados para la administración de ácidos nucleicos.

Country Status (11)

Country Link
US (1) US20220323594A1 (es)
EP (1) EP4010025A1 (es)
JP (1) JP2022543623A (es)
KR (1) KR20220045204A (es)
CN (1) CN114555130A (es)
AU (1) AU2020329156A1 (es)
BR (1) BR112022002449A2 (es)
CA (1) CA3149641A1 (es)
IL (1) IL290293A (es)
MX (1) MX2022001660A (es)
WO (1) WO2021030218A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11739162B2 (en) * 2019-09-09 2023-08-29 Brookhaven Science Associates Llc Side chain modified peptoids useful as structure-stabilizing coatings for biomaterials
WO2022032058A1 (en) * 2020-08-07 2022-02-10 Nutcracker Therapeutics, Inc. Multicomponent delivery systems for polyanionic cargo compound delivery
NL2029057B1 (en) * 2021-08-06 2023-02-21 Nutcracker Therapeutics Inc Compositions comprising hydroxyethyl-capped cationic peptoids
US20240307526A1 (en) * 2021-08-06 2024-09-19 Nutcracker Therapeutics, Inc. Compositions comprising hydroxyethyl-capped cationic peptoids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060697A2 (en) * 2003-12-19 2005-07-07 Chiron Corporation Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
EP3939571A1 (en) * 2015-05-21 2022-01-19 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Also Published As

Publication number Publication date
WO2021030218A1 (en) 2021-02-18
IL290293A (en) 2022-04-01
BR112022002449A2 (pt) 2022-05-03
US20220323594A1 (en) 2022-10-13
CN114555130A (zh) 2022-05-27
CA3149641A1 (en) 2021-02-18
EP4010025A1 (en) 2022-06-15
AU2020329156A1 (en) 2022-03-03
KR20220045204A (ko) 2022-04-12
JP2022543623A (ja) 2022-10-13

Similar Documents

Publication Publication Date Title
MX2022001660A (es) Composiciones peg de péptidos catiónicos lipidados para la administración de ácidos nucleicos.
ZA202101376B (en) Tertiary amino lipidated cationic peptides for nucleic acid delivery
MX2024001218A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
MX2018013919A (es) Portadores hibridos para cargas de acido nucleico.
MX2024010190A (es) Inclusion del exon2 inducida por antisentido en alfa-glucosidasa acida.
MX348474B (es) Lipidos, composiciones de lipido, y metodos de uso de los mismos.
MX2022013691A (es) Formulaciones que contienen lipidos.
MY168413A (en) Amino-substituted imidazopyridazines
EP3450552A3 (en) Improved enzyme variants
MX2022000183A (es) Lipidos cationicos y usos de estos.
WO2008093195A3 (en) Chitosan-based colloidal particles for rna delivery
NZ706588A (en) Methods for making lignocellulose containing composite products
EP2547209A4 (en) FUNGICIDAL COMPOSITIONS COMPRISING A PHOSPHATE SOLUBILIZING MICROORGANISM AND A FUNGICIDE ACTIVE COMPOUND
MX2020007477A (es) Formulacion para la administracion de arn.
GB201223100D0 (en) Feed compostion comprising a mineral complex and methods of using the mineral complex
MX2021012138A (es) Preparacion y almacenamiento de formulaciones de arn liposomico adecuadas para terapia.
WO2012058675A3 (en) Zinc oxide complexes
ZA202309527B (en) Ionizable lipids and compositions for nucleic acid delivery
WO2011071280A3 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
WO2012064146A3 (ko) Ｇｋｎ １을 함유하는 항암용 조성물
WO2008108808A3 (en) Complexes derived from heterohybrid cells and uses thereof
MX2015017854A (es) Composicion que comprende glutamico-n, n-diacetato (glda), agua y enzima.
IL285206A (en) Complexes that penetrate the cells and send nucleic acids to the lung
MX2023009850A (es) Composiciones y metodos para la administracion de acidos nucleicos.
PH12014501223A1 (en) Compositions and methods for the stability of reactive amino acids in a food matrix